Arrowhead Pharmaceuticals (ARWR) Accumulated Expenses (2010 - 2026)

Arrowhead Pharmaceuticals (ARWR) has 17 years of Accumulated Expenses data on file, last reported at $20.4 million in Q1 2026.

• Quarterly Accumulated Expenses rose 22.59% year-over-year to $20.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $20.4 million (up 22.59% YoY) and the FY2025 annual result came in at $26.9 million, up 22.31% from the prior year.
• Accumulated Expenses climbed to $20.4 million in Q1 2026, from $14.3 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $48.2 million in Q4 2022 to a low of $8.8 million in Q4 2023.
• A 5-year average of $27.0 million and a median of $23.7 million in 2022 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Accumulated Expenses jumped 790.87% — and 2023, when it plunged 81.78%.
• Tracing ARWR's Accumulated Expenses over 5 years: stood at $48.2 million in 2022, then slumped by 81.78% to $8.8 million in 2023, then gained by 28.46% to $11.3 million in 2024, then increased by 26.56% to $14.3 million in 2025, then jumped by 42.72% to $20.4 million in 2026.
• The last three Accumulated Expenses figures came in at $20.4 million (Q1 2026), $14.3 million (Q4 2025), and $26.9 million (Q3 2025), per Business Quant data.